Issue of 1m warrants9 Jul 2025 07:01
Exercise of Warrants
Cambridge, UK, 9 July 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage
biotechnology company developing next-generation kinase inhibitors for
autoimmune disease and cancer, announces that it has received a notice to
exercise certain warrants to subscribe for a total of 1,000,000 new ordinary
shares in the capital of the Company at a price of 12.5 pence per New Ordinary
Share (the "New Ordinary Shares") for a total consideration to the Company
of £125,000.
Admission and Total Voting Rights
Application has been made to the London Stock Exchange plc for the admission
of the 1,000,000 New Ordinary Shares to trading on AIM ("Admission"). It is
expected that Admission will occur at 8.00 a.m. (London time) on or around
Monday 14 July 2025. The New Ordinary Shares will rank pari passu with the
existing ordinary shares.
Immediately following Admission, the total number of ordinary shares in issue
will be 135,411,893. and the total number of voting rights will therefore
be135,411,893 and this figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the share capital
of the Company under the FCA's Disclosure and Transparency Rules.